Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Two Months To Add Two Words – Biosimilar Supplement Review Times May Be Hindering Uptake

Executive Summary

Biosimilar supplement approvals by the US FDA take on average about five months as sponsors request easier and quicker ways to update labels.

You may also be interested in...



FDA Publishes BsUFA III Commitment Letter Ahead Of 2022 Renewal

Following months of negotiations with industry and stakeholders, the FDA has released the commitment letter for the third iteration of its five-year Biosimilar User Fee Amendments program, marking another step ahead of its reauthorization.

BsUFA III Expands Biosimilar Supplement Review Goals To Speed Approvals

Six supplement categories based on submission content will be created with review goals between three and 10 months.

FDA Official Foresees Reduced Biosimilar Data Burden

New guidance from UK's MHRA saying comparative clinical efficacy studies typically will not be needed is a start, but other regulators may need a few years before adopting similar rules.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS125170

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel